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Abstract: A-kinase anchoring proteins (AKAPs) and cyclic nucleotide phosphodiesterases (PDEs)
are essential enzymes in the cyclic adenosine 3′-5′ monophosphate (cAMP) signaling cascade. They
establish local cAMP pools by controlling the intensity, duration and compartmentalization of cyclic
nucleotide-dependent signaling. Various members of the AKAP and PDE families are expressed in
the cardiovascular system and direct important processes maintaining homeostatic functioning of
the heart and vasculature, e.g., the endothelial barrier function and excitation-contraction coupling.
Dysregulation of AKAP and PDE function is associated with pathophysiological conditions in
the cardiovascular system including heart failure, hypertension and atherosclerosis. A number
of diseases, including autosomal dominant hypertension with brachydactyly (HTNB) and type I
long-QT syndrome (LQT1), result from mutations in genes encoding for distinct members of the
two classes of enzymes. This review provides an overview over the AKAPs and PDEs relevant for
cAMP compartmentalization in the heart and vasculature and discusses their pathophysiological
role as well as highlights the potential benefits of targeting these proteins and their protein-protein
interactions for the treatment of cardiovascular diseases.
Keywords: cAMP; compartmentalization; A-kinase anchoring proteins (AKAP); cyclic nucleotide
phosphodiesterases (PDE); PDE inhibitors
1. Introduction
Cardiovascular diseases (CVD) represent the leading cause of death worldwide and hypertension
is the main risk factor for such conditions [1]. Treatments targeting the causes of cardiovascular
diseases such as hypertension or heart failure are rare [2].
The second messenger cyclic adenosine 3′-5′ monophosphate (cAMP) is ubiquitous and functions
as a signal transducer of many extracellular cues [3]. It regulates a variety of biological processes
that are essential for, among others, proper cardiac function and it is involved in disease [4,5]. cAMP
exerts its effects via activation of downstream effector proteins, i.e., cAMP-dependent protein kinase A
(PKA), exchange proteins activated by cAMP (Epac) and cyclic nucleotide-gated ion channels (CNG),
hyperpolarization-activated cyclic nucleotide-gated channels (HCN) and the recently identified Popeye
domain containing (POPDC) proteins [6–8].
The plethora of extracellular signals, the limited number of intracellular cAMP effectors and
the requirement of a specific biological response to each of the external signals imply a tight control
of the intracellular signaling. This is achieved through signaling in defined cellular compartments.
Local cAMP pools are established by the interplay of essentially four processes within the cell, namely
cAMP synthesis, its diffusion, formation of multi-protein signaling complexes and cAMP degradation.
In the heart, stimulation of β-adrenoceptors (β-ARs) triggers the activation the α-subunits of the
stimulatory G proteins (Gs), which in turn stimulate adenylyl cyclases (ACs) to convert ATP to
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cAMP [9]. The formation of multi-protein signaling complexes in the cAMP signaling pathway is
orchestrated by the family of A-kinase anchoring proteins (AKAPs), which act as scaffolds and engage
in direct protein-protein interactions, including with PKA, and target them to defined subcellular
compartments [10–15]. AKAPs play essential roles both in the heart and vascular physiology by
coordinating complexes involved in the regulation of various processes including endothelial-barrier
function [16,17] cardiac contraction and relaxation [18–21] and action potential duration [22,23]. AKAPs
apparently play a role in several pathophysiological conditions in the cardiovascular system, e.g.,
in the heart their dysregulation is associated with heart failure [24,25].
Termination of cAMP signaling is predominantly achieved by hydrolysis of the phosphodiester
bond within the second messenger, a reaction catalyzed by cyclic nucleotide phosphodiesterases
(PDEs) [26]. Various PDE families regulate different aspects of cardiac and vascular muscle
functions [27], such as the endothelial barrier function [28,29], the Ca2+ handling and thus
contractility [30] and the basal pacemaking activity [31]. PDEs are also involved in the pathological
cardiac remodeling and dysfunction [4,32–35].
The aim of this review is to provide an overview over the AKAPs and PDEs that are relevant
in the compartmentalization of cAMP signaling in the cardiovascular system, to discuss their role
in physiology and pathophysiology and the potential of these proteins and their protein-protein
interactions as pharmacological targets in cardiovascular diseases.
2. A-kinase Anchoring Proteins (AKAPs)
AKAPs are a family of over 40 different scaffolding proteins and are key players in the
spatio-temporal control of cAMP-dependent signaling by targeting PKA and additional signaling
proteins including ACs, PDEs, further protein kinases and phosphatases to specific subcellular
compartments [11,36–38]. PKA is the major downstream effector of cAMP. It is a serine/threonine
kinase with broad specificity that controls many cellular processes, e.g., metabolism, cell growth,
cell division and cardiac myocyte contraction [39]. It is a heterotetramer that consists of two catalytic
subunits (Cα, Cβ or Cγ) kept in an inactive state by two regulatory RI (RIα or RIβ) or RII (RIIα or
RIIβ) subunits that are organized as homodimers in the holoenzyme [40]. Upon cAMP binding to
the R subunits, the C subunits are released and thus activated and subsequently phosphorylate local
substrates [39]. This view was recently confirmed by quantitative mass spectrometric analyses [41].
However, PKA holoenzyme can also be active, as indicated by early biochemical experiments [42,43].
This notion was supported by recent fluorescence resonance energy transfer (FRET) imaging-based
experiments, which suggested that physiological cAMP levels promote only minimal dissociation of
the C subunits from the holoenzyme, thereby limiting the range of PKA action to the substrates in
the immediate proximity [44]. Thus, it appears that both PKA holoenzyme and/or the dissociated C
subunits can be active.
The structural feature that all AKAPs share is their ability to bind PKA via their A-kinase binding
domains (AKBs), a structurally conserved amphipathic helix of 14–18 amino acids that docks into the
hydrophobic groove formed by the N-terminal dimerization/docking (D/D) domains upon R subunits’
dimerization (Figure 1) [45–48]. Despite the fact that most AKAPs bind to PKA-RII subunits [37,49],
there are the so-called dual specific AKAPs [50] that can bind both RI and RII subunits as well as
AKAPs that specifically bind RI subunits (e.g., sphingosine kinase interacting protein (SKIP) and
small membrane (sm) AKAP) [51–53]. Recently, hydrophilic anchor points have been identified within
and outside the amphipathic helix forming the AKB that are involved in determining the affinity of
the binding between an AKAP and the D/D domain. These observations suggest that targeting the
amino acids that act as anchor points could lower the binding affinity or even prevent the interaction,
making them candidates for pharmacological targeting. Moreover, targeting the anchor points makes
the development of selective inhibitors of specific AKAP-PKA interactions feasible [48]. Selective
inhibitory agents would be valuable tools for the investigation of cellular functions of individual
AKAP-PKA interactions and could be starting points for drug development efforts.
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Figure 1. Schematic representation of A-kinase anchoring proteins (AKAP)-protein kinase A (PKA)
interactions displayed at two different angles. The amphipathic AKB helix of AKAPs docks into the
hydrophobic groove formed by the dimers of the N-terminal D/D domains of regulatory subunits of
PKA. AKB A-kinase-binding domain; D/D dimerization and docking domain.
2.1. AKAP Subcellular Localization
Targeting of AKAPs to specific subcellular compartments is essential for a coordinated
cAMP-dependent signaling response, including accurate PKA-catalyzed substrate phosphorylation [54].
AKAPs can be directed to various cellular compartments, including the plasma membrane (PM,
e.g., AKAP18α, AKAP18β, AKAP79 [55–57]), the sarcoplasmic reticulum (SR, e.g., AKAP18δ [20]),
the cytosol (e.g., SKIP, GSKIP [51,58–61]), the cytoskeleton (e.g., gravin, ezrin [62]), the mitochondria
(e.g., D-AKAP1 [63]) and the nucleus (e.g., pericentrin and AKAP350 [64,65]).
2.2. AKAPs in the Cardiovascular System
Several AKAPs are expressed in the cardiovascular system (Table 1). They regulate a variety
of processes and are key proteins in maintaining the homeostatic functioning of the heart and
vasculature [66]. For instance, gravin and AKAP220 are involved in maintaining the vascular
integrity [16,17]. Homeostasis of the vascular tone is achieved through tight control of the balance
between contraction and relaxation of vascular smooth muscle cells (VSMC), processes in which
AKAP79 is involved [67,68]. Ca2+ handling and thus cardiac myocyte contractility is regulated by
several macromolecular protein complexes whose platforms are AKAPs, e.g., AKAP18α, γ and δ,
mAKAPβ [19–21,69]. The AKAP Yotiao is the key player in cardiac myocyte repolarization that follows
contraction [22]. Several AKAPs are involved in stress response-induced cardiac myocyte hypertrophy,
including AKAP-Lbc and mAKAPβ [70,71]. AKAP79 and gravin are important for the recycling of
β1-ARs and β2-ARs, respectively [72,73].
Table 1. Overview of AKAPs expressed in the heart and vasculature and of the cardiovascular processes
that they regulate.
Common Name Gene Name Alternative Name Regulated Cardiovascular Process
D-AKAP1 AKAP1 AKAP121/AKAP149/AKAP84 Cardiac stress response
D-AKAP2 AKAP10 - Cardiac repolarization
AKAP9 (long isoform) AKAP9 - Endothelial barrier function
AKAP18α
AKAP18γ
AKAP18δ
AKAP7 - Excitation-contraction coupling
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Table 1. Cont.
Common Name Gene Name Alternative Name Regulated Cardiovascular Process
AKAP79 AKAP5 AKAP75/AKAP150
Vascular tone;
Excitation-contraction coupling;
β-AR desensitization/resensitization cycle
AKAP220 AKAP11 - Endothelial barrier function
AKAP-Lbc AKAP13 Brx-1/Proto-Lbc/ Ht31 Cardiac stress response
mAKAPβ AKAP6 AKAP100 Excitation-contraction coupling;Cardiac stress response
AKAP Yotiao AKAP9 GC-NAP Cardiac repolarization
Gravin AKAP12 AKAP250 Endothelial barrier function;
β-AR desensitization/resensitization cycle
SKIP SPHKAP - Cardiac stress response
2.2.1. AKAPs Regulating the Endothelial Barrier Function
The vascular endothelium lining the intima of blood vessels consists of a layer of endothelial cells
tightly adherent to each other through cell-cell junctions. A healthy endothelium plays an essential
role in the proper functioning of the vascular system. It regulates macromolecular permeability
and anti-inflammatory, anti-thrombotic and anti-hypertrophic responses. Inflammatory conditions
trigger pathological changes in the vascular system that lead to endothelial dysfunction, a state in
which pathologically activated endothelial cells lose their barrier properties and initiate expression
of pro-inflammatory adhesion molecules on their surface [74]. This results in increased vascular
permeability allowing the infiltration of various molecules such as lipoproteins into the sub-endothelial
space, and of circulating immune cells (e.g., monocytes). Ultimately, this leads to severe pathological
conditions including atherosclerosis, allergy and sepsis [75,76].
AKAP-mediated PKA compartmentalization is essential for the maintenance of proper endothelial
barrier function [16,17,77]. The vascular endothelium integrity is mainly dependent on tight junctions
(TJs), important in sealing space between adjacent cells, and on adherens junctions, which assure
direct contacts with the actin cytoskeleton of neighboring cells, thus providing mechanical strength.
AKAP220 associates with PKA, β-catenin and the endothelial adherens junctions protein VE-cadherin,
tethering PKA in close proximity to the cell-cell junctions [16]. Gravin (also known as AKAP12
or AKAP250) promotes vascular integrity by regulating the actin cytoskeleton via p21-activated
kinase family proteins 2 (PAK2), an actin cytoskeletal regulator and afadin (AF6), a linker of the actin
cytoskeleton with intercellular adhesion molecules [17]. Rac1 is a member of the Rho family of small
GTPases, which upon activation strengthens the adherens junctions and the cortical actin skeleton,
thereby preserving the endothelial barrier [78]. Simultaneous depletion of gravin and AKAP220
inhibited cAMP-mediated Rac1 activation, underlining the importance of these AKAPs in preventing
endothelial dysfunction [16].
One other member of the AKAP family is involved in maintaining vascular integrity, the long
isoform of AKAP9. Following Epac1 activation, AKAP9 contributes to microtubule growth regulation
and is essential for preserving the endothelial barrier [79].
2.2.2. AKAPs Regulating the Vascular Tone
Homeostasis of the vascular tone is maintained by a tight balance between dilation and
constriction of blood vessel endothelium; the main regulator is the renin-angiotensin-aldosterone
system (RAAS). The main effector molecule of this system is angiotensin II (AngII), which exerts most
of its effects via angiotensin type I receptors (AT1R). For instance, arterial smooth muscle contraction is
induced by AngII-dependent stimulation of AT1R, localized at the sarcolemma, and subsequent
activation of phospholipase C (PLC), which catalyzes the hydrolysis of phosphatidylinositol
4,5-bisphosphate (PIP2) to diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG activates
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protein kinase C (PKC), which in turn phosphorylates L-type Ca2+ (CaV1.2) channels, thereby
increasing their open probability and increasing Ca2+ entry into the cytosol [75].
In arterial smooth muscle cells, the activity of a specific subpopulation of CaV1.2 channels is
regulated by AKAP79 (AKAP5/AKAP75/AKAP150)-dependent targeting of PKCα to the sarcolemma,
which facilitates phosphorylation of the channels and increases their open probablility [80]. By affecting
the opening probability of specific CaV1.2 channels, the AKAP79 complex regulates the so-called
“CaV1.2 sparklets”, which refers to local elevations of intracellular Ca2+ pools that directly induce
contraction of the VSMCs. The sparklets increase the vascular tone [67]. In addition, AKAP79
facilitates and most probably stabilizes the coupling of small clusters of adjacent CaV1.2 channels,
which can then open synchronously and generate large CaV1.2 sparklets, thus increasing the contractile
force [81,82]. Prolonged CaV1.2 channel activity and thus persistent CaV1.2 sparklets could lead to
vascular dysfunction and eventually contribute to AngII-induced hypertension [80].
Transient receptor potential vanilloid 4 (TRPV4) channels are Ca2+ permeant channels that
unlike the CaV1.2 channels, promote relaxation upon activation. Both CaV1.2- and TRPV4-mediated
Ca2+ influxes activate adjacent ryanodine receptors (RyR), leading to release of Ca2+ from the SR
into the cytosol in the form of Ca2+ sparks. While the CaV1.2-mediated Ca2+ influx increases
contraction, the local TRPV4-generated Ca2+ sparks activate the large-conductance, Ca2+-activated
K+ (BK) channels, which promote membrane hyperpolarization and closure of the CaV1.2 channels,
ultimately resulting in relaxation [83,84]. In the arterial smooth muscle cells, AngII increased TRPV4
activity via PKC, which is tethered to the sarcolemma in close proximity of the channel by AKAP79,
thus opposing the CaV1.2 channel-induced vasoconstriction [68].
In conclusion, AKAP79 plays an essential role in the control of arterial vascular tone by regulating
two opposing processes, contraction and relaxation of arterial myocytes.
2.2.3. AKAPs Controlling Excitation-Contraction Coupling
The cycling of Ca2+ between the cytosol and the SR is at the basis of cardiac contraction and
relaxation. Key players in these processes are L-type Ca2+ CaV1.2 channels, RyR2, SR Ca2+ ATPase 2
(SERCA2) and the Na+/Ca2+ exchanger. More specifically, upon sarcolemma depolarization, CaV1.2
channels located at the T tubules open allowing Ca2+ influx into the cardiac myocyte. This causes
Ca2+-induced Ca2+ release from the SR into the cytosol through RyR2 located at the SR. The Ca2+, upon
interaction with troponin T located on the thin myofibers, promotes contraction. Relaxation occurs via
SERCA2-mediated Ca2+ re-uptake into the SR and through Ca2+ transport out of the cell by Na+/Ca2+
exchangers [85]. SERCA2 is activated upon the phosphorylation and subsequent dissociation of
phospholamban (PLN), a SR phosphoprotein [20,86,87].
β-ARs introduce a further layer into the regulation of cardiac myocyte contractility.
Their stimulation induces PKA-dependent phosphorylation of several proteins involved in Ca2+
handling, e.g., the CaV1.2 channels, RyR2 and PLN. These phosphorylations are facilitated by
distinct AKAPs.
AKAP18α is a membrane-associated scaffolding protein and is the smallest AKAP7 gene
transcript, comprising 81 amino acids. AKAP18α promotes cardiac contractility by mediating the
PKA-dependent phosphorylation of CaV1.2 channels at Serine 1928 (Ser1928) on its α subunit and at
multiple sites on its β subunit, which enhances the open probability of the channel and increases the
Ca2+ current [69,88]. The activity of a subset of CaV1.2 channels associated with caveolin-3 (Cav3) is
regulated by PKA phosphorylation of the specific channel subpopulation mediated by an AKAP79
(AKAP5/AKAP75/AKAP150)-based macromolecular complex consisting of β-AR, PKA, AC5/6 and
protein phosphatase calcineurin (PP2B) [89]. The muscle selective AKAP, mAKAPβ (a short version
of mAKAP) associates with RyR2 at the SR and thereby facilitates the PKA phosphorylation of the
channel, leading to enhanced opening of the channel and subsequent enhanced Ca2+ release from
the SR into the cytosol [19]. In addition, mAKAPβ interacts with the Na+/Ca2+ exchanger 1 at the
sarcolemma and promotes the PKA-dependent activation of the exchanger, resulting in increased Ca2+
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efflux [90,91]. AKAP18δ (rat heart) and AKAP18γ (human heart) facilitate the PKA phosphorylation
of PLN and promote its dissociation from SERCA2 and hence activation of the ATPase, thus enhancing
the re-uptake of Ca2+ into the SR [20,21,92].
2.2.4. AKAPs Regulating Cardiac Repolarization
The cardiac repolarization phase is initiated by the slow heart potassium current (IKs) moving
outwards through the IKs potassium channel, a macromolecular complex consisting of a pore-forming
α subunit (KCNQ1) and a regulatory β subunit (KCNE1) along other intracellular proteins [93].
The AKAP Yotiao, the smallest transcript of the AKAP9 gene, is essential for cardiac repolarization
since it mediates the PKA-dependent phosphorylation of KCNQ1 and therefore regulates the activity
of the IKs potassium channel [22]. Mutations in the KCNQ1 subunit or Yotiao increase the duration of
the action potential and lead to type I long-QT syndrome (LQT1), a channelopathy that can elicit fatal
arrhythmia [94]. Another AKAP that contributes to the regulation of cardiac action potentials is the dual
specific D-AKAP2 (AKAP10). A single-nucleotide polymorphism (SNP) in its PKA binding domain
causes a decrease in the PR interval in the electrocardiogram, which in turn can cause arrhythmias and
sudden cardiac death [54,95–97].
2.2.5. AKAPs Involved in Cardiac Stress Response
Cardiac hypertrophy is a stress-induced adaptation to maintain normal heart function [23,25].
At the cellular level, it is characterized by the upregulation of specific genes that promote the
non-mitotic growth of cardiac myocytes [98]. AKAP-Lbc encodes in addition to its AKAP function
for a guanine nucleotide exchange factor (GEF) that directly binds and activates the GTP-binding
protein RhoA [99–102]. The interaction is involved in both cardiac development [103] and pathological
cardiac myocyte hypertrophy [70]. α1-AR stimulation enhances the RhoGEF activity of AKAP-Lbc,
which in turn activates RhoA, contributing to a pathological increase in the hypertrophic response [70].
PKA-mediated phosphorylation at Ser1565 of AKAP-Lbc leads to the recruitment of 14-3-3 proteins,
which inhibit the Rho-GEF activity of the anchoring protein [104]. Also, an AKAP-Lbc-dependent
signalosome mediates the activation and cytosolic release of activated protein kinase D (PKD),
which has been shown to promote cardiac hypertrophy by facilitating the nuclear export of histone
deacetylase 5 (HDAC5) [105,106].
Another AKAP that plays a central role in modulating stress signal-induced hypertrophic
pathways is mAKAPβ. It coordinates a variety of cAMP-responsive enzymes. This anchoring protein is
targeted to the nuclear envelope of cardiac myocytes via an interaction with nesprin-1α [107]. At the SR
it can integrate and transduce a variety of hypertrophic signals [71]. For instance, mAKAPβ-mediated
PKA phosphorylation and subsequent activation of RyR2 located at the nuclear envelope promotes
the activation and nuclear translocation of the pro-hypertrophic transcription factor nuclear factor
of activated T cells (NFAT) [108]. In addition, a mAKAPβ-based signalosome consisting of PKA,
PDE4D3, Epac1, ERK5 and PP2A promotes ERK5-induced cardiomyocyte hypertrophy [71,109].
Cardiac remodeling can also be regulated by hypoxia, a process in which a mAKAP-based protein
complex consisting of hypoxia-inducible factor 1α (HIF-1α), prolyl hydroxylase domain protein (PHD),
the von Hippel-Lindau protein (pVHL) and the E3 ligase designated seven in absentia homolog 2
(Siah2) plays a role. More specifically, when oxygen levels are reduced, mAKAP promotes the
degradation of PHD and thereby facilitates an increase in HIF-1α levels, which regulates transcription
of genes that promote cell survival [110].
Other AKAPs that are thought to be involved in the cardiac stress response are D-AKAP1 and
SKIP [111,112]. D-AKAP1 is a scaffolding protein of the outer mitochondrial membrane, which is
protective against cardiac hypertrophy since its overexpression leads to cardiac myocyte cell size
reduction and inhibition of the β-AR agonist isoproterenol-induced hypertrophy [111]. Moreover,
D-AKAP1 expression maintains the mitochondrial structure and function in the heart and reduces
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the infarct size, cardiac remodeling and mortality under conditions of ischemia, i.e., after myocardial
infarction [113].
SKIP plays an important role in the generation of the cardioprotective and anti-apoptotic
lysophospholipid sphingosine-1-phosphate (S1P) produced upon myocardial ischemia-reperfusion
injury [112]. It is involved in the regulation of sphingosine kinase type 1 (SPHK1), which upon
activation phosphorylates sphingosine to form S1P [114].
2.2.6. AKAPs Involved in the β-ARs Desensitization/Resensitization Cycle
Upon activation, β-ARs are phosphorylated and subsequently bind β-arrestin, which prevents
further ligand binding leading to receptor desensitization. The phosphorylated β-ARs are
internalized and reach the early endosomes where they undergo resensitization after PP2A-mediated
dephosphorylation. Upon resensitization, the non-phosphorylated receptors are recycled to the plasma
membrane where they can bind further ligands. Therefore, β-AR desensitization and resensitization
are essential processes in maintaining the proper functioning of the receptor [115].
Gravin and AKAP79 are important in the desensitization/resensitization cycle [72,73].
A gravin-based complex consisting of PKA, PKC, PP2B, β-arrestin and G protein-linked receptor
kinase 2 (GRK2) is essential for the desensitization and resensitization of the β2-ARs, with which
it interacts at their C-terminal tail [72]. AKAP79 mediates the PKA-dependent phosphorylation
of the β1-ARs by also binding to the C terminus of the receptor, leading to their recycling and
resensitization [73].
2.3. Aberrant cAMP Compartmentalization Can be Visualized
Dysregulation of local cAMP signaling is associated with cardiovascular diseases, e.g.,
maladaptive cardiac remodeling and heart failure [116,117]. FRET-based imaging using genetically
encoded sensors (cAMP-binding and PKA activity reporters) is utilized to visualize local
cAMP signaling components and real-time changes in cAMP levels with high spatio-temporal
resolution [118–121]. Such sensors can be targeted to various subcellular locations including in
cardiac myocytes in close proximity of sarcolemmal ion channels and SR proteins involved in Ca2+
handling, e.g., RyR2 and SERCA2a [122–125]. In addition, the FRET-based reporters can be used for
cAMP imaging in intact cardiac tissue as well as in ex vivo and in vivo hearts [126]. For monitoring
activities of signaling molecules in their cognate microdomains, FRET approaches have also been
combined with other techniques such as scanning ion-conductance microscopy (SICM), a non-optical
method that allows the imaging of both cell membrane morphology and functional parameters at
resolutions in the nanometer range [127–130].
3. Cyclic Nucleotide Phosphodiesterases (PDEs)
Hydrolysis by PDEs is the main route for lowering of intracellular levels of cAMP and cGMP
and is essential for the spatio-temporal regulation of cyclic nucleotide-dependent signaling [26].
The PDE superfamily consists of 21 genes that give rise to more than 100 proteins due to differential
transcription initiation sites and alternative splicing. PDEs are classified into 11 families (PDE1–PDE11).
They differ in their primary structures, substrate specificities, mechanisms of regulation and kinetic
properties [131]. Some PDE families selectively hydrolyze cAMP or cGMP, while others, the so-called
dual specific PDEs, catalyze the hydrolysis of both second messengers (Figure 2) [132].
PDEs display a common general structure consisting of three components: a family-specific
N-terminal regulatory domain, a conserved catalytic domain (25–52 % homology) and a C-terminal
domain that can be either phosphorylated by the mitogen-activated protein kinase (MAPK) or
prenylated [131,133–135]. The regulatory domains contain various structural features involved in the
regulation (i.e., sites for covalent modifications, e.g., phosphorylation), binding of regulatory molecules
(e.g., Ca2+-binding protein calmodulin), localization (targeting domains and protein-protein interaction
motifs, e.g., AKAP-binding motifs) and dimerization (e.g., GAF domains) of the enzymes [131,136,137].
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The catalytic domains feature in the active site a Zn2+ binding motif and an additional divalent metal
binding site that is most probably occupied by Mg2+, but could also correspond to Mn2+ and Co2+ [138].
Figure 2. Substrate specificity of individual phosphodiesterase (PDE) families.
3.1. PDE Subcellular Localization
The subcellular localization of PDEs is key in achieving compartmentalized cyclic nucleotide
signaling and, therefore, in the generation of specific physiological responses [136]. PDEs are located at
various intracellular locations, e.g., the cytosol (e.g., PDE3A3 and PDE5 [139,140]), plasma membrane
(e.g., PDE2A, PDE3A1, PDE6α, PDE6β [139,141,142]), the Golgi–centrosome (e.g., PDE7A1 [143]) and
nuclear regions (e.g., PDE9A1, PDE9A16, PDE9A17 [144]).
3.2. PDEs in the Cardiovascular System
Members from most PDE families are expressed in the cardiovascular system and regulate
a variety of processes essential for the proper functioning of the heart and vasculature (Table 2).
The PDE families 2, 3, 4 and 5, for example, regulate the endothelial barrier function and are,
therefore, of utmost importance in maintaining vascular integrity [28,145,146]. Several members
of the PDE families 2, 3, 4, 5 and 8 are involved in the control of cardiac contractility [30,120,147–150].
In addition, the basal pace-making activity of the sinoatrial (SA) node of the heart is regulated by
two PDE families, namely PDE3 and PDE4 [151]. In addition, various PDE family members, PDE1A,
PDE3A, PDE4B, PDE4D, PDE5 and PDE9A, are implicated in the cardiac stress response, which
triggers pathological cardiac remodeling and ultimately cardiac dysfunction (e.g., heart failure and
arrhythmias) [34,152–156].
Table 2. Overview of the PDE families expressed in the cardiovascular system and the corresponding
cardiovascular processes that they regulate.
PDE Family PDE Gene Substrate Specificity Regulated Cardiovascular Process
PDE1
PDE1A
cAMP, cGMP Cardiac stress responsePDE1B
PDE1C
PDE2 PDE2A cAMP, cGMP
Endothelial barrier function;
Excitation-contraction coupling
PDE3
PDE3A
PDE3B cAMP, cGMP
Endothelial barrier function;
Excitation-contraction coupling;
Basal pacemaking activity of the SA node;
Cardiac stress response
PDE4
PDE4A
cAMP
Endothelial barrier function;
Excitation-contraction coupling;
Basal pacemaking activity of the SA node;
Cardiac stress response
PDE4B
PDE4C
PDE4D
J. Cardiovasc. Dev. Dis. 2018, 5, 14 9 of 25
Table 2. Cont.
PDE Family PDE Gene Substrate Specificity Regulated Cardiovascular Process
PDE5 PDE5A cGMP
Endothelial barrier function;
Excitation-contraction coupling;
Cardiac stress response
PDE8
PDE8A
cAMP Excitation-contraction couplingPDE8B
PDE9 PDE9A cGMP Cardiac stress response
3.2.1. PDE3A and Autosomal Dominant Hypertension with Brachydactyly (HTNB)
PDE3A along with PDE3B belongs to the PDE3 family, also known as the cGMP-inhibited cAMP
PDE family, which is able to hydrolyze both cAMP and cGMP in a competitive manner. PDE3A
is highly expressed and plays important roles in VSMCs, cardiac myocytes, platelets and oocytes,
whereas PDE3B is mainly expressed in adipose and soft tissue. Upon alternative splicing, three
PDE3A isoforms are generated, namely PDE3A1 (136 kDa), PDE3A2 (118 kDa) and PDE3A3 (94 kDa)
(Figure 3A). They are located in different cellular compartments. PDE3A1 is the main isoform found
in human cardiac myocytes and is predominantly located at membranes. It contains two N-terminal
hydrophobic regions (NHR), of which the first one consists of four transmembrane domains. PDE3A2,
which lacks the first but contains the second NHR can be both membrane-associated and cytosolic and
is the main variant found in VSMCs. PDE3A3 is found only in the cytosol, since it lacks both previously
mentioned hydrophobic regions. All three isoforms possess the same catalytic region and present high
similarities regarding their catalytic activity and inhibitor sensitivity (Figure 3A) [157,158].
Mutations in genes encoding for distinct PDE family members can have detrimental effects
and cause specific human diseases. One such example is represented by the Mendelian syndrome
Autosomal-dominant hypertension with brachydactyly type E (HTNB), caused by missense mutations
in the gene encoding for PDE3A [159]. The syndrome is characterized by an age-dependent
progressive hypertension, brachydactyly type E and blood vessel hyperplasia [159]. If untreated,
blood pressure increases by 50 mm Hg and patients die from stroke before age 50 years. Surprisingly,
hypertension-associated end organ damage such as cardiac hypertrophy, kidney damage or
hypertensive retinopathy is low [160,161].
Eight mutations in PDE3A were discovered in eight unrelated families from Turkey, France,
the United States, South Africa, Canada, Netherlands and Japan. All these mutations were missense,
gain of function mutations and found in close proximity to each other. The identified mutations
cause amino acid substitutions in a region between amino acids 445 and 449 and increases of
PKA-mediated phosphorylation of serine residues 428 and 438 of PDE3A1 and PDE3A2. The region
is not present in PDE3A3 (Figure 3A) [159]. The substitutions lead to increased cAMP affinity and
hydrolytic activity of the enzymes (Figure 3B). In addition, the hyperactive enzyme is erroneously
localized in microsomal fractions from HeLa cells, suggesting that aberrant compartmentalization is
detrimental in the cardiovascular system [159,161]. VSMCs from patients expressing the hyperactive
version of the enzyme with the T445N substitution display higher proliferation rates, explaining the
vascular phenotype.
In the human heart, PKA-mediated phosphorylation of PDE3A1 induces its recruitment to
an AKAP18-based signalosome in the heart that controls the Ca2+ reuptake into the SR and thereby
participates in the control of cardiac relaxation [21]. An extended overview over functions of PDE3 in
the heart was provided in recent reviews (e.g., [162,163]).
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Figure 3. Schematic representation of the PDE3A gene, PDE3A protein isoforms and the
hyperphosphorylation caused by the identified mutations. (A) Eight mutations have been identified
in families from the countries indicated by the flags. The mutations cluster within a region of the
gene encoding amino acids 445 and 449. The mutations cause hyperphosphorylations of Ser428 and
Ser438. The N-terminal hydrophobic region (NHR) 1 of PDE3A1 comprises four transmembrane
domains, while NHR2 contains no typical transmembrane region but a cluster of hydrophobic amino
acids. PDE3A2 contains only NHR2 and PDE3A3 lacks all N-terminal hydrophobic regions (for details
see text). (B) The hyperphosphorylation increases cyclic adenosine 3′-5′ monophosphate (cAMP)
hydrolysis, causing low cAMP levels.
3.3. PDE Inhibitors
Due to their essential physiological and pathological roles in cyclic nucleotide signaling, PDEs are
considered pharmacological targets for a variety of cardiovascular diseases, including atherosclerosis,
hypertension, heart failure and intermittent claudication [26,164–166]. Several inhibitors of PDE3,
4 and 5 are approved as drugs, some of which are used for the treatment of cardiovascular diseases.
3.3.1. PDE3
The PDE3 inhibitor cilostazol is an antiplatelet agent with vasodilatory and antiproliferative
properties. It has been widely studied in a number of cardiovascular diseases including coronary
and peripheral artery diseases and cerebrovascular disease [167]. Cilostazol is administered for the
treatment of peripheral arterial circulatory disorders and also used as an antiplatelet agent in patients
that underwent carotid artery stenting [168,169]. In addition, it is also approved for the treatment
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of intermittent claudication-induced symptoms [170–172]. Cilostazol appears to be a promising
therapeutic agent for secondary prevention of stroke and was shown to improve right ventricular
systolic function as well as to decrease pulmonary artery pressure [167,173]. PDE3 inhibitors inhibit
neointima formation in a rat balloon double-injury model displaying neither cytotoxicity nor effects on
VSMC migration, and thus are considered targets in preventing acute re-occlusion after angioplasties,
e.g., percutaneous transluminal coronary angioplasty (PTCA) [174].
Milrinone is another PDE3 inhibitor. It has inotropic and vasodilatory properties, and is
widely used in patients with end-stage heart failure in order to temporarily improve cardiac
contractility (positive inotropic effect) and decrease vascular resistance. Taking into account
that long-term administration of milrinone can induce apoptosis of cardiac myocytes, cardiac
arrhythmias, hypotension and increases cardiovascular mortality, it is only used in a selected
group of patients [170,175–177]. A potential explanation for the long-term PDE3 inhibitor
therapy-induced mortality could be the fact that PDE3A inhibition induces cardiac myocyte apoptosis
via a PDE3A-inducible cAMP early repressor (ICER) feedback loop. More specifically, PDE3A
inhibition leads to PKA activation and ICER protein stabilization, which, in turn, promotes cardiac
myocyte apoptosis. Therefore, therapeutic strategies that would diminish PDE3A activity without
affecting the PDE3A-ICER feedback loop could promote the beneficial effects while by-passing the
side effects [152,162]. Current research aims at determining the effects of milrinone on pulmonary
hypertension and right ventricular failure, where it is believed to be particularly helpful [176].
3.3.2. PDE4
The PDE4 family is encoded by four genes, PDE4A, PDE4B, PDE4C and PDE4D [178] and was
shown to be involved in the excitation-contraction coupling regulation, especially in rodents. It has
been recently suggested that PDE4 inhibitors could be beneficial in treating sepsis in infants with
cardio-renal syndrome (CRS) since they are effective in improving cardiac function in a rat model
suffering from sepsis-induced acute cardiac dysfunction and kidney injury [179]. In addition, PDE4
depletion stabilized the endothelial barrier by reducing the atrial natriuretic peptide (ANP)-induced
vascular permeability and, therefore, was efficient in maintaining the plasma volume [180]. Despite the
fact that PDE4A, PDE4B and PDE4D are expressed in the human and rodent heart, with PDE4D being
the predominant isoform found in the human heart [181], there is no approval for a PDE4 inhibitor
for the treatment of cardiovascular diseases. A highly selective PDE4 inhibitor, roflumilast, has been
approved in various countries for the treatment of chronic obstructive pulmonary disease (COPD),
a chronic inflammatory lung disease characterized by heavily breathing due to obstructive airflow
from the lungs as well as a decline of lung function over time [182–184]. Another inhibitor, apremilast
is employed for the treatment of psoriasis [185].
3.3.3. PDE5
PDE5A is the sole gene coding for the PDE5 family, which plays an essential role in the
cardiovascular system. PDE5 expression is low in the healthy cardiac tissue, whereas it is upregulated
in the diseased heart [155,186]. PDE5 inhibition counteracts cardiac remodeling and fibrosis of
isolated cardiac fibroblasts via repression of transforming growth factor (TGF)-β1-induced Smad
signaling [187]. PDE5 depletion inhibits left ventricular remodeling induced by hypertrophic and
pro-fibrotic stimuli [188]. Reduction in PDE5 expression was beneficial for chronic heart failure
patients by enhancing the endothelium-dependent, flow-mediated vasodilation [189]. In addition,
high PDE5 expression was identified in the hypertrophic human right ventricle and its inhibition
enhanced contractility, particularly important for pulmonary hypertension [186]. PDE5 inhibitors
such as sildenafil, vardenafil and tadalafil are approved for the treatment of erectile dysfunction
and pulmonary hypertension but are not yet approved for the treatment of other cardiovascular
diseases [26]. Nevertheless, recent studies suggest potential therapeutic benefits for PDE5 inhibitors,
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i.e., sildenafil and tadalafil in the treatment of myocardial infarction, ischemia/reperfusion injury,
endothelial dysfunction, cardiac hypertrophy and heart failure [190,191].
3.3.4. Potential for PDE1, PDE2, PDE8 and PDE9 Inhibitors
PDE1, PDE2, PDE8 and PDE9 inhibition is considered a therapeutic opportunity for the treatment
of cardiovascular diseases but inhibitors are not approved.
The PDE1 family is encoded by three distinct genes, PDE1A, PDE1B and PDE1C, and is the
only PDE family activated by calcium/calmodulin (Ca2+/CaM) binding [192,193]. Due to their
potential to dilate coronary arteries, inhibition of PDE1 enzymes may be beneficial for the treatment
of coronary artery disease (CAD) and angina pectoris [194]. Nuclear PDE1A is important for the
proliferation of VSMCs and, therefore, could contribute to neointima formation in diseases, e.g.,
atherosclerosis and restenosis [195]. Thus, diminishing its expression could decrease pathological
neointima development. In addition, inhibition of the PDE1 family might improve cardiopathy and
pulmonary arterial hypertension since it decreases the structural remodeling process underlying these
two conditions [196].
PDE2A is the only gene coding for the PDE2 family and plays a central role in the cardiac CaV1.2
current regulation. The expression is up-regulated in human failing hearts [197,198]. Inhibition of PDE2
had a positive inotropic effect in dogs and mice, whereas its overexpression decreased the heart rate
in mice. Interestingly, in a heart-specific PDE2-transgenic mouse model, increased PDE2 abundance
prevents ventricular arrhythmias by inhibiting Ca2+ leak from the SR and helps in maintaining the
contractile function of the heart after myocardial infarction [199]. On the contrary, a recent study
in patients that had experienced an acute myocardial infarction (AMI) suggests that inhibition of
endothelial PDE2A could have a beneficial effect and improve the clinical outcome. Hypoxia and
pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) promote PDE2A activation, which
results in diminished submembrane cAMP levels and endothelial barrier disruption. This facilitates
the extravasation of activated neutrophils and leads to inflammation in the early post-myocardial
infarction phase [29].
The PDE8 family comprises two members, PDE8A and PDE8B and regulates excitation-contraction
coupling in ventricular myocytes. More specifically, it has been suggested that PDE8A controls at
least one cAMP pool involved in the cardiac myocyte-dependent Ca2+ cycling regulation. It was also
observed that PDE8A deletion caused both increased RyR2 leak as well as enhanced Ca2+ refilling of
the SR [150].
The PDE9 family is encoded by a single gene, PDE9A, and consists of more than 20 different splice
variants. PDE9A expression was identified in human and rodent hearts, where its expression increased
upon hypertrophy and heart failure development [156,200]. PDE9A depletion had a protective effect
for the heart against pathological remodeling caused by pressure overload and it reversed a previously
established heart disease without requiring the activity of NO synthase [156].
4. Concluding Remarks
Compartmentalized cyclic nucleotide signaling is found at the basis of precision of cellular
signaling and its dysregulation is associated with various pathological conditions including several
cardiovascular diseases. Local pools of cAMP are established by the interplay of cAMP synthesis,
diffusion, degradation as well as positioning of the relevant signaling proteins. AKAPs and
PDEs are essential players in these processes since they orchestrate the formation of multi-protein
signaling complexes and terminate local cAMP signaling, respectively. This interplay ensures the
spatio-temporal regulation of cyclic nucleotide-dependent signaling. Despite the fact that both
molecules are key elements in the cAMP signaling pathway, very little is known with respect to
their direct interaction or their interplay in the cardiovascular system. However, a few PDE-containing
AKAP complexes have been identified; examples are the SERCA2/AKAP18 signalosome, which
incorporates PDE3A1 upon its phosphorylation and is important for cardiac contractility, and the
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PDE4D3 containing mAKAPβ-based signalosome involved in cardiomyocyte hypertrophy regulation
([21,71,109]). Alterations in AKAP expression and their protein-protein interactions are associated with
various cardiovascular diseases [12,24]. Hence the development of pharmacological agents targeting
such dysregulated signaling components for evaluating their relevance as pharmacological targets
is needed. First examples show that targeting AKAPs and their protein-protein interactions with
small molecules is possible. For instance, an AKAP-PKA interaction inhibitor, FMP-API-1 [201]
was identified. Recently, a novel small molecule, Scaff10-8, was developed, which inhibits the
interaction of AKAP-Lbc and RhoA and prevents the AKAP-Lbc-mediated RhoA activation, an event
pathologically activated in models of cardiac hypertrophy [102]. Further molecules directed against the
AKAP-Lbc-RhoA interface have recently been identified and may serve to guide to further preclinical
drug development efforts [202,203].
Approved inhibitors of PDEs target the catalytic activities of PDEs. However, the catalytic
domains of the various members of individual families are identical and inhibition of one inhibits all.
This lack of selectivity presumably explains PDE inhibitor therapy-associated side effects, which are
frequent and dramatic over long-term administration [158]. PDE isoform-selective inhibition may be
achieved through disruption of specific protein-protein interactions. and therefore the displacement of
particular PDE isoforms from their subcellular compartments [204].
In conclusion, targeting proteins directing compartmentalized cAMP signaling, in particular
AKAPs and PDEs, not only serves to understanding their role in heart and vascular physiology
and pathophysiology but also has therapeutic potential for the treatment of a wide range of
cardiovascular diseases.
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